Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.

MLA

Brownlee, Wallace, et al. “Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: The CLARENCE Study.” Multiple Sclerosis and Related Disorders, vol. 79, Nov. 2023, p. 104951. EBSCOhost, https://doi.org/10.1016/j.msard.2023.104951.

APA

Brownlee, W., Amin, A., Ashton, L., & Herbert, A. (2023). Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study. Multiple Sclerosis and Related Disorders, 79, 104951. https://doi.org/10.1016/j.msard.2023.104951

Chicago

Brownlee, Wallace, Amerah Amin, Luke Ashton, and Alex Herbert. 2023. “Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: The CLARENCE Study.” Multiple Sclerosis and Related Disorders 79 (November): 104951. doi:10.1016/j.msard.2023.104951.